Physician profile
Deepali D Eksambe
NPI 1982946299
$1,634.88
in general payments reported to CMS, 2019-2025
21 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.78 · 2020: $91.94 · 2021: $91.85 · 2022: $286 · 2023: $301 · 2024: $335 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $420.32 | 2020-2025 | Briviact, Nayzilam, Fintepla |
| Jazz Pharmaceuticals INC. | $244.44 | 2023-2025 | Epidiolex |
| Neurelis, INC. | $166.17 | 2020-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $155.15 | 2023-2025 | Daybue |
| Sk Life Science, INC. | $102.26 | 2023-2024 | |
| Biocodex, INC. | $83.40 | 2025 | |
| Greenwich Biosciences, INC. | $69.97 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $67.21 | 2022 | |
| Sobi, INC | $48.99 | 2022-2023 | |
| Livanova USA, INC. | $42.89 | 2021-2022 | |
| Ptc Therapeutics, INC. | $32.16 | 2023 | |
| Itf Therapeutics LLC | $32.10 | 2025 | |
| Eisai INC. | $30.47 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $21.81 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $20.87 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.86 | 2023 | M-M-R II, Vaxneuvance, Vaxelis |
| Sumitomo Pharma America, INC. | $18.01 | 2024 | Aptiom |
| Biomarin Pharmaceutical INC. | $16.55 | 2024 | Brineura |
| Metacel Pharmaceuticals LLC | $15.27 | 2024 | Ozobax |
| Aquestive Therapeutics, INC. | $14.80 | 2021 | |
| Aucta Pharmaceuticals, INC. | $13.18 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepali Eksambe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.